Katherine Hanaway, MD
NPI 1457375727 · Obstetrics & Gynecology Physician · Cambridge, MA
Enrolled with Medicare as Practitioner - Obstetrics/Gynecology · source: CMS PECOS Public Provider Enrollment (2026.04.01)
Provider details
- NPI number
- 1457375727
- Entity type
- Individual
- Primary specialty
- Obstetrics & Gynecology PhysicianAllopathic & Osteopathic Physicians
- Credential
- MD
- Sex
- Female
- Sole proprietor
- No
- License
- 228971 (MA)
Specialties & taxonomies
Allopathic & Osteopathic Physicians
Profile Score
A profile completeness & documented-activity index — NOT a quality, outcomes, or patient-satisfaction rating.
- Registry tenure25% of score
19 yrs in NPPES registry
- Profile completeness25% of score
100% of core fields populated
- Practice footprint15% of score
1 documented practice location
- Medicare service volume (vs. specialty peers)25% of score
1,789 Medicare services, 2024 (ranked within specialty)
- Open Payments transparency10% of score
Has Open Payments disclosures (2024)
Medicare volume is ranked against active providers in the same specialty. Signals a provider has no public data for (e.g. Medicare claims) are left out of the score entirely — never counted as zero — so providers without that data are not penalized. See the full formula and weights in our .
What this provider does (Medicare)
Based on Medicare fee-for-service claims, 2024; not all care is captured.
| Service (HCPCS) | Medicare services | Typical Medicare-allowed (2024) |
|---|---|---|
| Automated Urinalysis Test81003 | 358 | $2 |
| Bacterial Colony Count, Urine87086 | 278 | $8 |
| Ultrasound Measurement of Bladder Capacity After Voiding51798 | 236 | $13 |
| Bacterial Culture for Aerobic Isolates87077 | 178 | $8 |
| Evaluation of Antimicrobial Drug (antibiotic, Antifungal, Antiviral), Microdilution Or Agar Dilution87186 | 163 | $8 |
| Established Patient Office Or Other Outpatient Visit With Moderate Level of Decision Making, If Using Time, 30 Minutes Or More99214 | 151 | $140 |
What this provider prescribes (Medicare Part D)
Top drugs by Medicare Part D claim volume, 2024 · 18 distinct drugs on file.
| Drug | Part D claims (2024) | Beneficiaries |
|---|---|---|
| Vibegronbrand: Gemtesa | 288 | 72 |
| Estradiol | 279 | 158 |
| Mirabegronbrand: Myrbetriq | 242 | 81 |
| Mirabegronbrand: Mirabegron Er | 108 | 34 |
| Cephalexin | 100 | 38 |
| Nitrofurantoin Monohyd/M-Crystbrand: Nitrofurantoin Mono-Macro | 87 | 65 |
| Cefuroxime Axetilbrand: Cefuroxime | 48 | 33 |
Transparency — industry payments
Based on CMS Open Payments, 2024; not all care is captured.
$463 across 4 records (Open Payments 2024)
Open Payments discloses payments and transfers of value (meals, travel, consulting, research, royalties) from drug and device makers to providers. This is a transparency signal, not a verdict — such payments are legal and common, and their presence is neither an endorsement nor a criticism. Source: CMS Open Payments, program year 2024.
Practice location
Mailing address
Registry dates
- Enumerated
- 2006-07-27
- Last updated
- 2007-09-12
Source: CMS NPPES Data Dissemination (June 2026). NPI Central is not affiliated with CMS. Data is provided as-is from the public registry.